Peng Wang1, LiangLiang Xu1, Lian Li1, ShengSheng Ren1, JianWei Tang1, Ming Zhang2,3, MingQing Xu4. 1. Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 2. Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 48284728@qq.com. 3. Department of General Surgery, Mianzhu Hospital of West China Hospital, Sichuan University, Mianzhu, Sichuan, China. 48284728@qq.com. 4. Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. xumingqing@scu.edu.cn.
Abstract
BACKGROUND: The prognostic value of microRNA-375 (miR-375) expression in squamous cell carcinoma (SCC) had been reported in the previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic significance of miR-375 expression in SCC based on all eligible evidences. METHODS: Relevant studies were identified by searching PubMed, Embace, Medline, Cochrane Library, and China Biology Medicine disk. Survival outcome including overall survival (OS) and other survival outcomes were used as the primary endpoint to evaluate the prognostic outcome of patients with SCC. All statistical analyses were performed in RevMan software version 5.3 and STATA software version 14.1. Furthermore, the quality of included studies was assessed by The Newcastle-Ottawa Scale. RESULTS: In total, 13 studies, including 1340 patients, met the inclusion criteria for our meta-analysis. The pooled analysis results indicated that downregulation of miR-375 significantly predicted poor OS (HR 1.58, 95% CI 1.34-1.88, P < 0.001). Downregulated miR-375 was also correlated with the other survival outcomes. Subgroup analysis based on tumor type found that lower expression of miR-375 was significantly related with poor OS in patients with esophageal squamous cell carcinoma (ESCC) (HR 1.58, 95% CI 1.29-1.94, P < 0.001) and head and neck squamous cell carcinoma (HNSCC) (HR 1.59, 95% CI 1.16-2.18, P = 0.004). CONCLUSIONS: This meta-analysis demonstrated that the downexpression of miR-375 was significantly correlated with poor OS in patients with SCCs and indicated the potential clinical use of miR-375 as a molecular biomarker, particularly in assessing prognosis for patients with ESCC and HNSCC.
BACKGROUND: The prognostic value of microRNA-375 (miR-375) expression in squamous cell carcinoma (SCC) had been reported in the previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic significance of miR-375 expression in SCC based on all eligible evidences. METHODS: Relevant studies were identified by searching PubMed, Embace, Medline, Cochrane Library, and China Biology Medicine disk. Survival outcome including overall survival (OS) and other survival outcomes were used as the primary endpoint to evaluate the prognostic outcome of patients with SCC. All statistical analyses were performed in RevMan software version 5.3 and STATA software version 14.1. Furthermore, the quality of included studies was assessed by The Newcastle-Ottawa Scale. RESULTS: In total, 13 studies, including 1340 patients, met the inclusion criteria for our meta-analysis. The pooled analysis results indicated that downregulation of miR-375 significantly predicted poor OS (HR 1.58, 95% CI 1.34-1.88, P < 0.001). Downregulated miR-375 was also correlated with the other survival outcomes. Subgroup analysis based on tumor type found that lower expression of miR-375 was significantly related with poor OS in patients with esophageal squamous cell carcinoma (ESCC) (HR 1.58, 95% CI 1.29-1.94, P < 0.001) and head and neck squamous cell carcinoma (HNSCC) (HR 1.59, 95% CI 1.16-2.18, P = 0.004). CONCLUSIONS: This meta-analysis demonstrated that the downexpression of miR-375 was significantly correlated with poor OS in patients with SCCs and indicated the potential clinical use of miR-375 as a molecular biomarker, particularly in assessing prognosis for patients with ESCC and HNSCC.
Authors: Kar Lok Kong; Dora Lai Wan Kwong; Tim Hon-Man Chan; Simon Ying-Kit Law; Leilei Chen; Yan Li; Yan-Ru Qin; Xin-Yuan Guan Journal: Gut Date: 2011-08-03 Impact factor: 23.059
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Kristyna Hudcova; Martina Raudenska; Jaromir Gumulec; Hana Binkova; Zuzana Horakova; Rom Kostrica; Petr Babula; Vojtech Adam; Michal Masarik Journal: Tumour Biol Date: 2016-07-20
Authors: Dong Hwahn Kahng; Gwang Ha Kim; Su Jin Park; Sora Kim; Moon Won Lee; Bong Eun Lee; Hoseok I Journal: J Korean Med Sci Date: 2022-06-20 Impact factor: 5.354
Authors: Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis Journal: Int J Mol Sci Date: 2022-07-26 Impact factor: 6.208
Authors: Howard Yang; Hua Su; Nan Hu; Chaoyu Wang; Lemin Wang; Carol Giffen; Alisa M Goldstein; Maxwell P Lee; Philip R Taylor Journal: BMC Cancer Date: 2020-05-06 Impact factor: 4.430